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Abstract: Midkine (MK) is a heparin-binding cytokine, and promotes growth, survival, migration and other activities of target cells. Af-
ter describing the general properties of MK, this review focuses on MK and MK inhibitors as therapeutics for diseases in the central 
nervous system. MK is strongly expressed during embryogenesis especially at the midgestation period, but is expressed only at restricted 
sites in adults. MK expression is induced upon tissue injury such as ischemic brain damage. Since exogenously administered MK or the 
gene transfer of MK suppresses neuronal cell death in experimental systems, MK has the potential to treat cerebral infarction. MK might 
become important also in the treatment of neurodegenerative diseases such as Alzheimer’s disease. MK is involved in inflammatory dis-
eases by enhancing migration of leukocytes, inducing chemokine production and suppressing regulatory T cells. Since an aptamer to MK 
suppresses experimental autoimmune encephalitis, MK inhibitors are promising for the treatment of multiple sclerosis. MK is overex-
pressed in most malignant tumors including glioblastoma, and is involved in tumor invasion. MK inhibitors may be of value in the treat-
ment of glioblastoma. Furthermore, an oncolytic adenovirus, whose replication is under the control of the MK promoter, inhibits the 
growth of glioblastoma xenografts. MK inhibitors under development include antibodies, aptamers, glycosaminoglycans, peptides and 
low molecular weight compounds. siRNA and antisense oligoDNA have proved effective against malignant tumors and inflammatory 
diseases in experimental systems. Practical information concerning the development of MK and MK inhibitors as therapeutics is de-
scribed in the final part of the review. 
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1. INTRODUCTION 
  Midkine (MK) is a heparin-binding growth factor or cytokine 
that promotes growth, survival, differentiation, migration and other 
activities of target cells [1-3]. MK plays important roles in repro-
duction, development and repair, and is involved in the onset and or 
progression of inflammatory diseases and malignancy. Therefore, 
both MK and MK inhibitors are expected to aid in the treatment of 
various diseases.  
  MK is rich in both basic amino acids and cysteine, and has a 
molecular weight of around 13 kDa [4]. Pleiotrophin (PTN), also 
called heparin-binding growth-associate molecule (HB-GAM), has 
about 50 % sequence identity to MK [5-8]. However, the two are 
not closely related to other proteins.  
  MK is strongly expressed during embryogenesis, especially at 
the midgestation stage, but is expressed only in highly restricted 
sites in adults [1-3, 9]. MK becomes expressed upon tissue injury 
and malignant transformation [1-3, 10, 11]. This restricted mode of 
expression makes MK a suitable target for drug development. 
  Here I review MK and MK inhibitors as potential therapeutics 
to treat diseases of the central nervous system, such as ischemic 
brain injury upon cerebral infarction, glioblastoma, multiple sclero-
sis and neurodegenerative diseases. MK and MK inhibitors will 
have broad areas of application and are expected to be used also to 
treat other diseases such as heart failure and other malignancies.  
  I first describe the general properties of MK relevant to the 
main subject, and then focus on MK in diseases of the central nerv-
ous system and drug development. MK has been dealt with in ear-
lier reviews [1-3, 12]. 
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2. GENERAL PROPERTIES OF MK 
2.1. Historical Background 
  MK was found as the product of a gene whose expression in-
creased at early stage of the retinoic acid-induced differentiation of 
murine teratocarcinoma stem cells called embryonal carcinoma 
cells [13]. PTN was found as a factor to promote neurite outgrowth 
of embryonic neurons [14] or as a factor to promote growth of fi-
broblasts [15]. The deduced protein sequence of MK was published 
in 1990 [4]; that of PTN subsequently [5, 6]. A heparin-binding 
protein found in chicken embryos [16], called retinoic acid-induced 
heparin-binding [17], is the chicken form of MK. Human MK was 
cloned later [18, 19] and was also called heparin-binding neurotro-
phic factor [19] or neurite growth-promoting factor 2. 
2.2. Protein 
  MK and PTN are present in all vertebrates examined so far 
including Xenopus lavis [20] and zebrafish [21]. There are two MK 
genes in zebrafish due to gene duplication (Mdka and Mdkb) [21]. 
Drosophila melanogester lacks them, but has miple-1 and -2, with 
repeated motifs common to MK and PTN [22]. 
  Human MK and mouse MK have 87 % sequence identity [18], 
while human MK and Xenopus MK have about 60 % [20]. Posi-
tions of all 10 cysteine residues are conserved in MK of different 
species and also in PTN (Fig. 1). Furthermore, tryptophane residues 
are present downstream of the first cysteine residues forming two of 
the domains of MK and PTN. This feature is the same as that of the 
thrombospondin type I repeat; MK as well as PTN can be consid-
ered to belong to the thrombospondin superfamily [23]. 
  MK and PTN are largely composed of two domains, the more 
N-terminally located N-domain and the more C-terminally located 
C-domain [24] (Fig. 2). The N-domain has three disulfide linkages, 
while the C-domain has two. Both domains contain three antiparal-
lel β-sheets [25] (Fig. 1), but the C-domain also contains a flexible 
loop [25]. Besides the two domains there are an N-terminal tail (N-
tail), a C-terminal tail (C-tail) and a hinge connecting the two do-
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not confined to the two domains, but extends to the two tails and 
the hinge (Figs. 1, 2). Interestingly the hinge is the most conserved 
structure between MK and PTN. There is a large stretch of se-
quence around the hinge highly conserved between human and 
Xenopus MK and zebrafish Mdka (Fig. 1). The tails of MK do not 
form stable structures, and the two domains appear to move freely 
to each other [25]. 
Fig. (2). Domain structure of human MK. Homology to human PTN is more 
than 60 % (black color), between 40 – 60 % (grey color), or less than 40 % 
(white color). 
  Deletion of either the N-tail or C-tail strongly inhibited the 
neurite-promoting activity of MK [26]. However their role appears 
to be to keep the two domains apart, since the C-terminal half (C-
half) alone or even the C-domain shows a considerable degree of 
neurite-promoting activity [26, 27]. In the case of PTN, the C-tail 
itself is involved in its activity [28]. 
  The C-half of MK has stronger heparin-binding activity than 
the N-terminal half (N-half) [27]. Indeed, there are two heparin-
binding sites (Cluster-1 and -2) in the C-domain [25, 29]. Cluster-1 
(K79, R81, and K102) is composed of basic amino acids in two β-
sheets (Fig. 1). Cluster -2 (K86, K87, and R89) is on a flexible loop 
[25]. Cluster 1 is present in PTN, but Cluster -2 is not. W69, con-
served in the thrombospondin superfamily, is in aβ-bulge and its 
chemical shift upon NMR spectroscopy is changed by the addition 
of a heparin oligosaccharide [25]. There are also other amino acids 
which are likely to be involved in heparin-binding as shown by 
chemical shift changes [25]. 
  Because of important roles of carbohydrate recognition in MK 
activity to be mentioned later, the role of the two heparin-binding 
sites in MK activities has been systematically studied. Mutation of 
either of the two heparin-binding sites significantly reduces its neu-
rite-promoting activity [26, 29]. However, binding to one of the 
MK receptors, receptor-like protein tyrosine phosphataseζ(PTPζ) 
requires Cluster-1, but not Cluster-2 [30]. The enhancement of 
plasminogen activator activity in endothelial cells requires Cluster-
2 rather than Cluster-1 [26].  
  MK forms a dimer through spontaneous association and also by 
cross-linking with transglutaminase, and heparin promotes the di-
merization [31]. N-terminal half is required for the dimer formation 
[31]. Dimerization enhances MK activity to elevate the plasmino-
gen activator activity of endothelial cells, and A41-P51 peptide, 
which contains the site required for dimerization by transglu-
taminase, inhibits the MK activity [31]. Furthermore, it has been 
suggested that upon dimerization Cluster-2 fuses to form a large 
binding site [25].  
  The C-tail is the site primarily recognized by rabbit anti-MK 
antibodies [27]. However, monoclonal antibodies directed at the C-
domain or N-domain are available.  
2.3. Gene 
  The human MK gene, MDK, is located on chromosome 11 at 
p11.2 [32], while the mouse MK gene, Mdk, is on chromosome 2 
[33]. MDK is flanked by the diacylglycerol kinase z gene and mus-
carinic cholinergic receptor 4 gene [21, 34] (Fig. 3). The human 
PTN gene, PTN is located on chromosome 7 at q33 [35], and is also 
flanked by a diacylglycerol kinase gene and a muscarinic choliner-
gic receptor gene [21, 34], indicating that MDK and PTN have 
evolved from a common ancestor through gene duplication [21]. 
MDK and Mdk span about 3 kb, while PTN is very large, about 
130 kb [34, 36, 37]. MDK contains 4 coding exons and 3 non-
coding exons [34] (Fig. 3). In spite of the size difference, the intron 
/ exon organization of PTN is similar to that of MDK [38]. There is 
a variant MK mRNA, which lacks an exon and encodes a truncated 
MK [39].  
  The expression of MDK and Mdk is controlled by a variety of 
factors. Consistent with the induction of its expression by retinoic 
acid, there is a functional retinoic responsive element in the pro-
moter region [40, 41] (Fig. 3). Glucocorticoid regulates the expres-
sion of MK through binding of its complex with the receptor to the 
Fig. (1). Protein sequence of human MK. Amino acids conserved between MK of different species (human MK [18], Xenopus MK [20] and zebrafish Mdka 
[21, 194]) are shown by open boxes, while those conserved between MK and PTN (human MK and PTN [6], Xenopus MK and zebrafish Mdka) are shown by 
★. Heparin binding sites Cluster 1 and 2 are shown by closed hexagons and open hexagons, respectively. Bars show  -sheets. 
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promoter [42]. MK is strongly expressed in Wilms’ tumor cells 
[10], probably due to a loss of function of the tumor suppressor 
geneWT1. Indeed, a functional WT1-binding site is present in the 
promoter region of MDK [43] (Fig. 3). MK expression after 
ischemic reperfusion injury and MK overexpression in malignant 
tumors can be explained at least partly by the presence of a hypoxia 
responsive element in the promoter [44]. MK expression induced 
by reactive oxygen species [45] indicates that there is still another 
region in the promoter responsible for the induction.  
2.4. In Vitro Activities and Signal Transduction 
  MK promotes various activities of target cells, such as growth 
[46-48], survival [49-52], migration [30, 53-55], neurite outgrowth 
[46, 47, 56] and protein production [57-60] (Table 1). Among them, 
promotion of survival and that of migration are the central func-
tions. 
  MK is a heparin-binding protein [61]. The recognition of acidic 
carbohydrate chains such as heparin is essential for MK activity, 
since heparin inhibits many function of MK [55, 56] and digestion 
with either heparitinase or chondroitinase abolishes responsiveness 
to MK [26, 56, 62]. Oligomers of two different structures bind to 
MK strongly. One is heparan sulfate trisulfated unit found in hepa-
rin, and the other is chondroitin sulfate E unit found in chondroitin 
sulfate E [63-66]. Affinities of the two structures to MK are at the 
similar level as shown by surface plasmon resonance, MK affinity 
chromatography and the inhibition of MK-dependent neurite out-
growth [63-66]. Related structures in chondroitin-4 sulfate, chon-
droitin-6 sulfate and chondroitin sulfate D showed little or no activ-
ity.  
 PTPζ is the most established component of the MK receptor. 
It is involved in MK-dependent migration of neurons [30] and os-
teoblast-like cells [55] as well as promotion of cell survival by MK 
[67]. PTPζ is a proteoglycan and is a transmembrane protein with 
an extracellular chondroitin sulfate chain and cytoplasmic tyrosine 
phosphatase domain [68]. It binds to MK with the affinity of 0.58 
nM, but after removal of chondroitin sulfate chain, the affinity de-
creases to 8.8 nM [30]. Therefore, MK is likely to bind mostly to 
the chondroitin sulfate portion of PTPζ. PTPζ is also a receptor 
of PTN [69]. 
  The MK receptor is a molecular complex containing proteogly-
cans. Other proteoglycans with MK-binding activity are syndecans 
[70-72], glypican-2 [73], versican / PG-M [74] and neuroglycan C 
[75]. Neuroglycan C serves as an MK receptor for the promotion of 
neurites in oligodendrocyte precursor-like cells [75]. 
  Low density lipoprotein receptor-related protein (LRP), integrin 
α4β1 and integrinα6β1 were identified as MK-binding proteins 
in embryonic mouse brain and shown to be components of the MK 
receptor complex [76, 77]. LRP binds to MK with an affinity of 3.5 
Table 1.  Activities of MK to Target Cells 
Target cells   Activities 
Fibroblasts  Growth [46], Contraction of collagen gells 
[196], 
Synthesis of collagen and glycosaminoglycans 
[58] 
Keratinocytes Growth  [197] 
Endothelial cells  Fibrinolytic activity [57] 
Renal epithelial cells   MIP-2 production [59] 
Smooth muscle cells   Migration [54], IL8 production [60] 
Myoblasts   Clustering of acetylcholine receptor [198] 
Osteoblast-like cells   Migration [55] 
Embryonic neurons  Survival [49-52], Neurite outgrowth [46, 47, 
56] 
 Migration  [30] 
Neural precursor 
cells 
Growth [109], Survival [109] 
Oligodendrocyte  Neurite outgrowth [75] 
  precursor-like cells  
Neutrophils Migration  [53] 
Macrophages   Migration [54] 
Tumor cells  Growth [47, 48, 126] 
nM. Related molecules LRP6 and apoE receptor 2 also bind to MK 
strongly [67]. 
  Anaplastic lymphoma kinase (ALK) has been proposed as a 
receptor of MK [78, 79]. However, whether ALK binds to this 
molecule with high affinity is a matter of debate. Notch-2 is also an 
MK receptor upon epithelial-mesenchymal transition of immortal-
ized keratinocytes [80]. 
  LRP and integrin α4β1 or α6β1 have been found to bind 
strongly to each other [77]. PTPζ [77] and ALK (Muramatsu H et
al, unpublished) also formed a complex with LRP and the integrins, 
while either of PTPζ and ALK could be in the complex (Mu-
ramatsu H et al, unpublished). Therefore it is likely that LRP and 
Fig. (3). Organization of the human MK gene (MDK). Closed boxes show coding sequences in exons, and open boxes show noncoding sequences in exons. 
There are 3 non-coding exons. Usually, an MK mRNA has one of the non-coding exons. Open star, a retinoic acid-responsive element [41]; closed star, a 
functional WT1-binding site [43]. 
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integrins form the core of the complex, and other molecules such as 
PTPζ and ALK are recruited to the complex. MK has been shown 
to increase complex formation of the receptor components [77]. 
There is evidence that neuroglycan C also functions in the receptor 
complex (Ichihara et al., unpublished). 
  The response to MK stimulation is increased tyrosine phos-
phorylation of cytoplasmic proteins such as paxillin [77], and a Src 
family kinase is involved in the process [55, 62]. A hypothesis ex-
plaining MK signaling upon the promotion of cell migration has 
been proposed [3, 77]. Among 2 reports on the action of PTPζ as 
the PTN receptor [81, 82], one supports the above hypothesis [81]. 
The downstream signaling system of the MK receptor includes 
MAP kinase and PI3 kinase [52, 55, 79]. Then, suppression of 
caspases [52, 83] or enhancement of Bcl-2 [84] occurs upon the 
promotion of cell survival. After its activation by MK, ALK phos-
phorylates insulin receptor substrate-1; the signal is transmitted by 
MAP kinase and PI3 kinase and results in the activation of NFκB
[79]. Furthermore, the activities of STAT1α, STAT3 and STAT5 
are regulated by MK [80, 85-87]. 
  In addition to the signaling system mentioned above, MK is 
likely to function directly in the nucleus. Nucleolin, a shuttle pro-
tein moving between the cell surface and nucleus, has been identi-
fied as an MK-binding protein [88]. After binding to LRP, MK is 
internalized and transported to the nucleus by binding to nucleolin 
or laminin binding protein precursor [89, 90]. This nuclear transport 
of MK is important for MK-dependent cell survival [89]. Further-
more, MK in the nucleolus is involved in the synthesis of ribosomal 
RNA [91].  
2.5. MK in Differentiation and Development  
  MK is intensely expressed in the midgestation stage in mice [9, 
70]. From its distribution, MK has been implicated in epithelial-
mesenchymal interactions, neurogenesis and mesoderm remodeling 
[9, 70]. MK is generally more intensely expressed in the epithelial 
layer than mesenchymal layer [9]. Analysis of the development of 
the tooth germ in vitro has verified the role of MK in epithelial-
mesenchymal interactions [92]. MK appears to inhibit excessive 
action of BMP, which induces translucent zone in the mesenchyme 
[92]. Furthermore, the mode of action of MK during epithelial mes-
enchymal interactions has been revealed by an artificial blood ves-
sel model, in which collagen gel with smooth muscle cells is cov-
ered by blood vessel endothelial cells [60]. In this model, endothe-
lial cells express MK, which acts on smooth muscle cells to induce 
IL-8 expression. IL8 then promotes the growth of endothelial cells. 
Thus MK plays a central role in the complex interactions of the 
epithelial and mesenchymal cells. During lung development, MK 
produced by the epithelial cells promotes the development of mes-
enchymal tissue [93].  Concerning the remodeling of the meso-
derm, the introduction and expression of MK cDNA induces chon-
drogenesis by precursor cells [94]. Furthermore, MK induces adi-
pocyte formation from 3T3-L1 cells [86]. On the other hand, MK 
decreases trabecular bone volume [95]. The role of MK in neuro-
genesis is dealt with in the subsequent section. 
  In spite of the various in vitro activities of MK, mice deficient 
in the MK gene show only few abnormalities in development [96]. 
The same is true for mice deficient in the PTN gene [97]. However, 
mice deficient in both the MK and PTN genes were born with a 
frequency 1/3 of that expected by Mendelian segregation [98], 
small in size [98] and frequently died before adulthood (Muramatsu 
H et al, unpublished). Furthermore, the female double knockout 
mice exhibited infertility [98]. These results have established that 
MK and PTN have important roles in reproduction and develop-
ment. 
  MK and PTN are strongly expressed in granulosa cells in the 
ovary [98]. An analysis of the ovaries of the double knockout mice 
have revealed that follicular maturation is suppressed [98]. Deficit 
in follicular maturation caused by the lack of MK and PTN in 
granulosa cells has been concluded to be the primary reason of the 
female infertility. 
  In relation to the above-mentioned activity of MK, MK pro-
motes the process of in vitro maturation of oocytes, fertilization and 
subsequent development to blastocysts [99, 100]. This activity of 
MK might be of practical importance.  
2.6. Neurogenesis  
 In  Xenopus embryos MK expression first occurs in neural anla-
gen, then increases when the neural tube is formed. Embryos in-
jected with MK mRNA into the vegetal blastomeres develop ab-
normally and yield truncated tadpoles [101]. Histological examina-
tion have revealed that neurogenesis is enhanced and mesoderm 
differentiation is suppressed. The effect is stronger on injection into 
the dorsal than ventral blastomeres. Enhanced neurogenesis and 
suppressed mesoderm differentiation are also observed in excised 
animal caps treated with activin, when MK mRNA was preinjected. 
Based on the expression of neural markers, the induced neural tis-
sue has been concluded to be anterior [101].  
  The zebrafish has two MK genes due to gene duplication: Mdka 
is expressed in the paraxial mesoderm [102], and Mdkb in the neu-
ral plate [103]. Mdka is involved in determining whether a popula-
tion of midline cells become floor plate cells, which make up the 
basal portion of the neural tube and develop into the corresponding 
portion of the spinal cord [102]. Mdka is a factor, which determines 
the cell fate of the precursor cells either to floor plate cells or to 
notochord cells. Mdkb is required for the specification of cell fates 
at the neural plate border and for the development of neural crest 
cells and sensory neurons [103]. 
  In relation to the above finding, antisense oligonucleotide to 
MK inhibits the conversion of mesenchyme to neuroectoderm in 
cultured tail bud cell of chiken embryos [104]. Furthermore, mice 
deficient in the MK gene show moderate auditory deficits, and mice 
doubly deficient in both MK and PTN show severer deficits [105, 
106]. 
  At the midgestation stage in mice and rats, MK is strongly ex-
pressed in the basal layer of the cerebral cortex, which is rich in 
neural precursor cells including neural stem cells, and also in radial 
glial processes, which are extended processes derived from neural 
stem cells [9, 107, 108]. Differentiated neurons migrate along radial 
glial processes. MK is also strongly expressed in neural precursor 
cells in culture and is involved in their growth and survival [109]. 
Thus, neural precursor cells from MK-deficient mice grew poorly 
on dishes coated with poly-L-lysine but grew well on dishes coated 
with MK [109]. 
  MK is strongly expressed in the rat cerebellum 7 days after 
birth [110]. MK is probably involved in migration and neurite out-
growth in these cells. 
2.7. Repair and Inflammation 
MK is generally expressed in response to tissue damage such as 
ischemic injury in the brain [11], heart [111], kidney [59] and blood 
vessels [54]. MK can promote the repair of damaged tissue by en-
hancing the survival of injured cells [111-114]. Anti-bacterial activ-
ity of MK [115] would also be beneficial to tissue repair.  
  On the other hand, MK promotes inflammatory responses by 
enhancing the migration of inflammatory leukocytes such as neu-
trophils [53] and macrophages [54], increasing synthesis of 
chemokines [59], and suppressing the production of regulatory T 
cells [87]. An excessive inflammatory response is harmful to tissue 
repair. 
  The phenotype of MK-deficient mice is helpful in determining 
whether MK induced upon injury is beneficial or harmful to tissue 
repair (Table 2). For example, MK is concluded to promote the 
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Table  2  Phenotypes of MK-Deficient Mice in Relation to 
Diseases 
Diseases Phenotypes 
Heart failure  Enhanced damage and decreased survival 
upon ischemic heart damage [111] 
Peripheral nerve injury Delay in both degeneration and regeneration 
[199] 
Hepatitis  Decrease in liver regeneration upon partial 
hepatectomy [200] 
Nephritis  Decreased renal damage upon ischemia [59], 
chemotherapy [201] and diabetics [202] 
Hypertension  Decreased hypertension after 5/6 nephrec-
tomy [45] 
Rheumatoid arthritis  Decreased arthritis upon antibody-induced 
arthritis [151] 
Multiple sclerosis  Decreased neurological symptom upon EAE 
[87] 
 Restenosis  Decreased neointima formation after ischemic
injury [54] 
Adhesion after surgery Decreased adhesion [203] 
Cancer   Decreased lung metastasis [173] 
Osteoporosis  Increased trabecular bone formation [95] 
Alzheimer’s disease  Increased deposition of amyloid  -peptide 
plaques [179] 
greater in MK-deficient mice than wild-type mice [111]. Further-
more, MK-deficient mice die more frequently from ischemic heart 
damage [111]. However, MK is concluded to be harmful to the 
kidney after ischemic renal injury, since the damage to the renal 
tissue is more extensive in wild-type mice than MK-deficient mice 
[59]. Similar phenomena have been observed in other inflammatory 
diseases (Table 2).
2.8. Cancer 
  MK is overexpressed in most of human malignant tumors, such 
as carcinomas of the oral cavity [116], esophagus [117], stomach 
[117], colon [117], liver [117], pancreas [118], lung [119], urinary 
bladder [120], prostate [121], breast [122], uterus [123, 124] and 
ovary [125], osteosarcoma [126], soft tissue sarcoma [127], neuro-
blastoma [128], astrocytoma [129 ], meningioma [130], and acute 
lymphoblastic leukemia [131]. The overexpression is usually found 
in about 80 % cases of respective tumors, as in hepatocellular car-
cinoma [117], colon carcinoma [117], lung carcinoma [119] and 
prostate carcinoma [121]. MK overexpression is often detected 
even in the precancerous stage [132, 133]. In the carcinogenesis of 
colon cancer, MK becomes detectable in the moderate and severe 
stages of dysplasia [132]. A gradual increase in MK expression 
accompanying the progression of disease has also been observed 
[121, 129]. Furthermore, the strong expression of MK in tumors is 
often correlated with a poor prognosis [116, 118, 120, 121, 124, 
128, 129]. One reason for the overexpression of MK in tumors is 
the presence of a hypoxia responsive element in the MK promoter 
[44]. Loss of activity of the product of a tumor suppressor gene also 
leads to MK overexpression [43, 134]. 
  Overexpression of MK has been concluded to contribute to the 
malignant properties of cancer cells. As an example, transfection 
with MK cDNA transforms NIH3T3 cells [135]. Furthermore, MK 
overexpression is correlated with resistance to chemotherapy [136, 
137]. Generally speaking, MK is considered to be involved in tu-
mor invasion by promoting the growth, survival [138], migration 
and angiogenic activity [139] of tumor cells.  
  Because of its general overexpression in human cancers, MK 
has been the subject of intense research as a tumor marker. Indeed, 
serum or plasma levels of MK increase in the majority of patients 
with various malignant tumors [140-149]. The urinary MK level is 
also useful for detecting cancer in certain cases [150]. Serum MK 
levels are especially helpful in the detection of α-fetoprotein-
negative hepatocellular carcinoma [146]. Furthermore, high levels 
of MK in serum or plasma have been correlated with poor progno-
sis [145, 147, 148]. Since serum MK levels also increase in patients 
with rheumatoid arthritis [151], Alzheimer’s disease [152] and 
chronic heart failure with a high risk of cardiac events [153], the 
utility of MK as a tumor marker may be confined to apparently 
healthy subjects. 
  A truncated MK produced by alternative splicing may be of 
interest as a tumor marker because of its tumor-specific expression, 
occurrence in lymph node metastasis and contribution to the malig-
nant characteristics [39, 154-157] 
  MK is also promising as a molecular target to treat malignant 
tumors, and the MK promoter can be used for the tumor-specific 
expression of a gene for curative purposes. These points will be 
mentioned in a later section in relation to the treatment of glioblas-
tomas. 
2.9. Other Diseases 
  MK is correlated with hypertension, since it is a regulator of the 
renin-angiotensin system [45, 158]. Upon 5/6 nephrectomy, MK is 
expressed in the lung, and induces the expression of angiotensin-
converting enzyme [45]. Hypertension is induced after the nephrec-
tomy in wild-type mice but not significantly in MK-deficient mice 
[45]. 
  MK is also involved in the secretion of insulin. A complex of 
apolipoprotein A-V and MK is internalized and induces insulin 
secretion in rat pancreatic β-cells [159]. A possible association of 
MK with diabetes is an interesting subject to be examined.  
3. TREATMENT OF DISEASES OF THE CENTRAL NERV-
OUS SYSTEM  
3.1. Neuronal Death Upon Cerebral Infarction 
  Delayed neuronal death occurs around an area of the infarct 
referred to as the ischemic zone and upon the sudden opening of 
blood stream after an infarction, and is a serious complication of 
cerebral infarction. 
  MK expression upon cerebral infarction was first observed in 
the rat [11]. Experimental infarction was produced in the left cere-
bral cortices of rats by permanent occlusion of the middle cerebral 
artery. Immunohistochemical staining has revealed MK expression 
in edematous and periischemic areas around the infarct. The infarct, 
characterized by the shrinking or necrosis of neurons, does not ex-
press MK. The expression is found as early as Day 1 after occlu-
sion, is intense till Day 4, becomes weak on Day 7, and disappears 
on Day 14. The cells expressing MK have been identified as astro-
cytes [160] 
  MK is also expressed after transient forebrain ischemia in rats 
[161]. Before the ischemic insult, a basal level of MK is observed 
in hippocampal neurons notably CA1 pyramidal neurons, cortical 
neurons and the choroid plexus. Following 20 min of forebrain 
ischemia and reperfusion, MK expression decreases till Day 2. A 
decrease is observed in both the number of MK-expressing cells 
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the insult, many scattered cells around the CA1 pyramidal layer 
intensely express MK. These cells have been identified as reactive 
astrocytes. 
  The induction of MK expression after ischemia implied a role 
for MK in the prevention of neuronal death. Indeed, the intraven-
tricular injection of MK was found to ameliorate delayed neuronal 
death in the hippocampus after transient forebrain ischemia in ger-
bils [113]. The ischemia was achieved by occluding the bilateral 
common carotid arteries for 5 min. Examination after 7 days re-
vealed extensive neuronal death in the CA1 region of the hippo-
campus. The number of surviving cells in the CA1 region was 
17±25 / mm after ischemia reperfusion, and 265±38 / mm without 
the treatment (sham operation). The injection of MK solution im-
mediately before the occlusion greatly improved the survival of 
hippocampal neurons. After the administration of 2 μg MK, the 
number of surviving cells on Day 7 after ischemia increased to 
254±68 / mm. Consistent with this result, the number of TUNEL-
positive cells in the CA1 region after transient ischemia decreased 
upon the injection of MK. However, there were two problems. 
First, MK administered 2 h after ischemia reperfusion was not sig-
nificantly effective. Second, the neurons survived to Day 7 and then 
progressively died, and the effect of MK became insignificant on 
Day 28. 
  Cell death in the periischemic area after infarction is suppressed 
by postischemic gene transfer and expression of MK [162]. Cere-
bral infarction was produced by photochemical occlusion of the 
distal middle cerebral artery in spontaneously hypertensive rats. 
Ninety minutes after the occlusion, an adenoviral vector with 
MKcDNA (adeno-MK) was injected into the lateral ventricle on the 
ischemic side. Two days after the infarction, the infarct was signifi-
cantly smaller in rats transfected with adeno-MK than in those 
transfected with a control adenovirus: the reduction in infarct vol-
ume on the transfer of adeno- MK was 41 %. At the same time 
point, TUNEL-positive cells in the periischemic area were reduced 
to about 20 % of the control value by treatment with adeno-MK.  
  The reduction in infarct volume by adeno-MK was found even 
7 days after infarction [163]. Treatment with adeno-MK does not 
significantly alter the number of infiltrating macrophages and pro-
liferating neural precursor cells. However, the number of neural 
precursor cells migrating toward the infarct is increased by the 
treatment. All these results clearly indicate that MK expression 
induced by ischemic injury in astrocytes suppresses neuronal death. 
Although MK helped to prevent neuronal death after postischemic 
treatment in one of the two studies mentioned above, the difference 
is probably due to the difference in the animal model used and not 
to the method of supply or expression of MK. MK is expected to be 
clinically helpful to reduce infarct volume by rescuing neurons in 
periischemic regions. As a supportive evidence, MK administered 
shortly after ischemia reperfusion injury suppresses the death of 
heart cells in the mice [111]. 
  A neuroprotective effect of MK has also been clearly demon-
strated by another study. Temporal lobe epilepsy is a major type of 
epilepsy, and characterized by neuronal loss in subregions of the 
hippocampus. An excellent animal model of temporal lobe epilepsy 
is the seizure caused by an intracerebroventricular injection of kai-
nic acid [164] 
  Twenty-four hours after kainic acid is injected, basal levels of 
MK immunoactivity present in hippocampal pyramidal neurons 
decreases, while the number of MK-positive cells in the stratum 
lacunosum moleculare of CA3 markedly increases. The MK-
positive cells are astrocytes and not microglia [164].  
  Administration of MK together with kainic acid is able to sup-
press the seizures [164]. The seizures lasted for mean 1,201 sec 
without treatment, and for mean 319 sec in mice treated with 0.4 
μg of MK. When the intensity of the seizures was scored, the   
maximum score was 5.0 when jumping, circling, or rolling was 
observed. The mean score was 4.2 without treatment, and was 1.7 
with 0.4 μg of MK.  
  The extensive degeneration of neurons observed in hippocam-
pal subregions after the kainic acid treatment is significantly re-
duced by the administration of MK. The effect was strongest in the 
hilus, in which the number of neurons was reduced to about 15 % 
of that before the treatment with kainic acid. In the mice adminis-
tered with MK, however, about 82 % of the neurons in that region 
survived. A majority of neurons also survived in CA3 after the 
administration of MK. Loss of GABAergic interneurons after kainic 
acid treatment was also significantly suppressed in the strata pyra-
midale (68 % improvements) and radiatum (45 %) of CA3 and 
molecular layer (27 %), granular cell layer (29 %) and dentate hilus 
(33 %) of the dentate gyrus [164]. 
  These results illustrate the strong neuroprotective effect of MK. 
The effect was found at low doses: the maximum dose of MK was 
0.4 μg per mouse. The effect of MK was dose-dependent, and a 
higher dose of MK might achieve further protection. 
3.2. Multiple Sclerosis 
  Multiple sclerosis is an autoimmune disease characterized by 
inflammatory demyelination in the central nervous system. Experi-
mental autoimmune encephalitis (EAE) is an animal model of mul-
tiple sclerosis. Recent studies have revealed that MK is involved in 
the etiology of EAE [87].  
  EAE induced by the injection of myelin oligodendrocyte glyco-
protein peptide is less severe in mice deficient in the MK gene than 
in wild-type mice [87]. Supplying MK to the deficient mice abol-
ishes the suppression of EAE. Inflammatory cells infiltrate the spi-
nal cord to much lesser extent in the deficient mice, but on the sup-
ply of MK the infiltration resumes [87]. 
  The number of CD4+ CD25+ regulatory T cells in lymphoid 
tissues at the onset of the disease is greater in MK-deficient EAE 
mice than wild-type EAE mice [87]. The most plausible explana-
tion of this finding is that MK suppresses the expansion of regula-
tory T cells. This point has been verified by using cultured spleen 
cells: MK at the concentration of 20 – 100 ng / ml effectively sup-
presses the expansion. Furthermore, in MK-deficient mice, Th1 and 
Th17 cells, which mediate autoimmune disease, are suppressed as 
shown by the levels of cytokines produced by these cells. 
  These results indicate that MK suppresses regulatory T cells, 
thereby increasing Th1 and Th17 activities, and thus plays a key 
role in the onset of EAE. Therefore, suppression of MK activity is 
expected to suppress EAE. Indeed, an aptamer directed at MK has 
been found to exhibit such activity [87]. 
  RNA aptamers have high specificity and affinity for target 
molecules and are reported to have advantages over antibodies. The 
RNA aptamer used for the study was a 49-mer, and was stabilized 
with ribose-2’ modifications as well as cholesterol and inverted dT 
tags at the 5’ and 3’ ends. The Kd of the aptamer to MK was esti-
mated to be 0.9 nM. The anti-MK aptamer induced expansion of 
regulatory T cells in vitro. This aptamer was i. p. injected to mice 
every other day from the start of immunization with myelin oli-
godendrocyte glycoprotein peptide. The treated mice showed a 
retarded onset of EAE and lower clinical scores. The highest dose 
of the aptemer, 15 mg /kg, had the greatest effect. The aptamer was 
effective even when it was administered after the onset of EAE 
[87]. 
  These results indicate that anti-MK therapy is a promising 
treatment for multiple sclerosis. RNA aptamers might be the best 
choice for treating pathological regions in the spine. Low molecular 
weight inhibitors of MK, once they are developed, should also be 
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3.3. Glioblastoma 
  Glioblastoma or glioblastoma multiforme is a common form of 
brain tumor known for an aggressive nature and very poor progno-
sis. Glioblastoma belongs to tumors derived from astrocytes, collec-
tively called astrocytomas. MK expression has been found to in-
crease during the progression of human astrocytomas [129]. Thus, 
MK mRNA or protein is scarcely expressed in control brain tissue, 
weakly in low grade glioma, moderately to strongly in anaplastic 
astrocytoma and strongly in glioblastoma. MK overexpression was 
found in all of 9 glioblastoma specimens. The overexpression of 
MK appears to contribute to the malignant phenotypes of glioblas-
toma such as enhanced angiogenesis. 
  The strong expression of MK in glioblastoma is of significance 
for treatment. Indeed, an MK-promoter-based conditionally repli-
cating adenovirus (Ad-MK) exhibits strong oncolytic effects on 
malignant glioma cells, but not normal brain cells [165]. Ad-MK 
was constructed by placing a 0.6-kbp fragment from the MK pro-
moter in the 5’ region of the E1A gene in the adenovirus genome 
[166]. The 0.6-kbp fragment exhibits 2 orders of higher promoter 
activity in malignant glioma cells than in normal brain cells. Fur-
thermore, the injection of Ad-MK completely eradicates xenografts 
of malignant glioma [165]. 
  Ad-MK also suppresses the growth of xenografts of pancreatic 
carcinoma [167] and bladder carcinoma [168]. Ad-MK constructed 
in a different manner is effective for purging bone marrow tumors 
[169]. The MK promoter is suitable for tumor-specific gene expres-
sion because of its strong activity, ability to function in a broad 
range of tumor cells and lack of activity in most non-cancerous 
cells. For example, the promoter fragment acts as efficiently as the 
α-fetoprotein promoter in hepatocarcinoma cells [170].
  The tumor-specific nature of the MK promoter was clearly il-
lustrated in the following experiment. The thymidine kinase gene 
was placed under the control of the MK promoter or cytomegalovi-
rus (CMV) promoter in a replication-deficient adenoviral vector 
[171]. On the local administration of either adenoviral construct 
followed by gancicrovir treatment, the growth of xenografted 
Wilms’ tumor was suppressed almost completely. However after 
systemic delivery and ganciclovir treatment, the construct with the 
CMV promoter killed mice, whereas the construct with the MK 
promoter did not [171]. This is because thymidine kinase under the 
control of the CMV promoter was expressed in the liver and exhib-
ited hepatic toxicity in the presence of ganciclovir. The MK pro-
moter is inactive in the liver, and no sign of hepatic toxicity was 
found after transfection of the construct with the MK promoter. 
  All these results illustrate the utility of the MK promoter and its 
fragment for the tumor-specific expression of oncolytic viruses or 
therapeutic proteins. Further refinements of the methods may lead 
to novel therapeutic treatments for glioblastoma.  
  Strategies to suppress MK expression were not employed to 
treat glioblastoma in experimental models. However, siRNA or 
antisense oligoDNA to MK has been used to suppress the growth of 
other tumors. Thus, injection of antisense oligoDNA to mouse MK 
into mouse colorectal carcinoma pregrown in nude mice with the 
aid of atelocollagen effectively inhibits tumor growth [48]. siRNA 
to human MK suppresses the growth of human prostate carcinoma 
implanted in nude mice only moderately. However, a combination 
of the siRNA and taxol abolishes the tumor growth almost com-
pletely, at a taxol concentration at which only a partial inhibition of 
tumor growth is attained [172]. Therefore, even at the present stage 
of development, siRNA to human MK augments the effect of che-
motherapy. The relatively less effect of siRNA to human MK to 
inhibit tumor growth might be partly due to the presence of host 
MK, which is of mouse origin, and might not be inhibited by the 
reagent. Indeed the lung metastasis of MK-negative Lewis carci-
noma inoculated into the leg is much less extensive in MK-deficient 
mice compared to that in wild-type mice [173]. Nevertheless, an 
antisense oligoDNA to human MK effectively suppresses the 
growth of xenografted human hepatocarcinoma, when delivered by 
nanoliposomes [174].  
  Thus, methods of inhibiting the expression of MK should be 
considered as an option for treating glioblastoma. Suppression of 
PTN and ALK expression has already been employed as means to 
treat glioblastoma, and promising results have been obtained in 
animal experiments [175]. 
  In addition to siRNA or antisense oligoDNA, drugs which in-
hibit the action of MK should be tested against glioblastoma, when 
they become available. 
3.4. Neurodegenerative Diseases and Neuropsychiatric Diseases 
  MK has been found to accumulate in senile plaques in the brain 
of patients with Alzheimer’s disease. Senile plaques and neurofi-
brillary tangles are the two major pathological hallmarks of Alz-
heimers’s disease and closely associated with the pathology of the 
disease.  
  Immunohistochemical staining revealed the presence of MK in 
the senile plaques in cerebral cortex of all 8 patients with Alz-
heimer’s disease but not in the control specimens from 3 individu-
als without neurological diseases [176]. In consolidated plaques, the 
core was more intensely stained than the periphery. After formic 
acid treatment, the intensity of the staining was increased, and al-
most all amyloid β-peptide plaques were stained by the anti-MK 
antibody. Western blotting confirmed that the MK-like immunore-
activity detected immunohistochemically was MK itself [176]. 
Elevated serum levels of MK are also detected in about half of pa-
tients with Alzheimer’s disease [152]. 
  MK has been found to inhibit cytotoxicity [177] and polymeri-
zation [178] of amyloid β-peptide. Therefore, MK appears to be 
produced to counteract the deposition of amyloid β-peptide 
plaques. Indeed, the deposition of amyloid β-peptide plaques de-
rived from transgene was more extensive in mice deficient in the 
MK gene than in wild-type mice [179]. Furthermore, MK promoted 
the migration of microglias, which are involved in the clearance of 
amyloid β-peptide plaques [179]. Thus, MK is likely to counteract 
the deposition of amyloid β-peptide plaques by both directly bind-
ing to amyloid β-peptide and promoting the migration of micro-
glias. 
  MK immunoreactivity is also present in neurofibrillary tangles 
in brains of patients with parkinsonism-dementia complex of Guam 
[180]. MK is deposited in glial cytoplasmic inclusions in patients 
with multiple system atropy [181]. MK expression is also intense in 
the prefrontal cortex of chronic alcoholics [182]. In the rat hippo-
campus, chronic administration of morphine and yohimbine also 
increases MK expression [183]. In all these cases MK can be con-
sidered to be induced to counteract neural damage.  
  In MK-deficient mice, abnormal brain function was found only 
before adulthood at the initial phase of analysis [96]. Recent studies 
however, have revealed that dopamine D1 and D2 receptors and 
dopamine itself are decreased in the striatum of adult MK-deficient 
mice [184]. MK promotes the survival of mesencephalic neurons in 
culture [50]. Thus, MK deficiency may have resulted in the dys-
function or decrease of dopaminergic neurons in these mice. 
NMDA receptors and NMDA-receptor-related amino acids in the 
hippocampus and frontal cortex are not altered in the deficient 
mice.  
  Prepulse inhibition has been found to decrease in the hypodo-
paminergic MK-deficient mice [184]. Decreased prepulse inhibition 
is observed in patients with neuropsychiatric disorders including 
schizophrenia and autistic disorders. Treatment with antipsychotic, 
namely haloperidol or clozapine, restores prepulse inhibition to a 
level indistinguishable from that of wild-type mice [184]. Further-
more, MK-deficient mice exhibit reduced numbers and longer peri-
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be considered as a model of a subtype of schizophrenia character-
ized by a hypodopaminergic state.  
  The design of new treatments for the diseases mentioned in this 
section requires more basic research. The administration of MK to 
treat neurodegenerative diseases such as Alzheimer’s disease, 
which has a long clinical process, might not be practical. A more 
likely application is the enhancement of the growth and survival of 
a certain cell population upon regenerative therapy. MK has re-
cently been shown to promote the growth of embryonic stem cells 
[185]. Furthermore, MK expressed in neural precursor cells pro-
motes their growth and survival [109]. In addition, full understand-
ing of the MK promoter may aid the development of new drugs for 
treating neurodegenerative diseases, since such knowledge may 
make it possible to screen compounds which activate the MK gene 
in brain cells but not in precancerous cells. Concerning improve-
ment of the hypodopaminergic state, it will be important to know 
whether the supply of MK in the adult is effective for the purpose. 
4. DRUG DEVELOPMENT 
4.1. MK Protein 
  MK is useful to suppress neuronal death especially upon 
ischemic injury [113]. MK has been produced as a recombinant 
protein in yeast [186], baculovirus [56], L cells [46] and Es-
cherichia coli [88], and also chemically synthesized [187]. So far 
the most widely used preparation to promote cell survival is the one 
produced by yeast. Yeast-made MK is effective to promote survival 
of neurons [113] and heart cells [111, 112]. It can be obtained in 
relatively large amounts and at least the major portion is likely to be 
properly folded. However, aberrant glycosylation, especially man-
nosylation, might occur under certain conditions. Production in 
mammalian cells is an alternative choice. However, the cells should 
be rigorously checked as to whether they produce MK of their own 
even in small amounts. Contamination with MK from different 
species may not be easily removed during purification. MK pro-
duced by L cells is effective to promote the survival of photorecep-
tor cells exposed to constant light [114]. 
  MK has 5 disulfide linkages [24]. Therefore, attention should 
be paid so that only the molecule with correct disulfide linkages is 
used. In the chemical synthesis of MK, half molecules (N-half and 
C-half) were separately synthesized. These half molecules were 
fractionated by HPLC to isomers with different disulfide bridges. 
After structural analysis, only the ones with correct disulfide 
bridges were connected by chemical means to yield the MK mole-
cule [187]. When the scrambling of disulfide linkages occurs exten-
sively in a preparation of recombinant MK, a similar approach can 
be used to produce the recombinant protein, since chymotrypsin 
cleaves MK into halves [188].  
  Since MK is an adhesive protein, care is needed not to lose it 
through absorption to vessels, especially upon storage. Our recom-
mended conditions for storage are -80 
0C in 50 mM phosphate 
buffer pH 6.8 containing 1 – 0.5 M NaCl with an MK concentration 
of more than 0.1 mg/ml [66]. Repeated freezing and thawing should 
be avoided. With higher MK concentrations, storage under lower 
NaCl concentrations may be possible. High concentrations of NaCl 
can be removed by dialysis prior to usage. To dilute the stock solu-
tion of MK, vessels are preferably coated with silicon. 
  Potential side effects of MK can be enhanced inflammation and 
promotion of carcinogenesis. It is proper to mention that response 
to MK is different in individual organs, and enhanced inflammation 
was not reported upon treatment of ischemic injury in the brain and 
heart by MK [111, 113]. Concerning promotion of carcinogenesis, 
administration of MK for short time period is expected to be harm-
less, since MK is an endogenous factor induced after injury. More 
caution is required for prolonged application of MK.  
4.2. MK Inhibitors 
  Various MK inhibitors are now used to treat malignant and 
inflammatory diseases in experimental models. siRNA and an-
tisense oligoDNA are much frequently used [48, 172, 174, 189-
192] (Table 3), and might be applied to the treatment of glioblas-
toma.  
Table  3.  Inhibitors of MK in Treatment of Diseases Upon 
Experimental Systems 
Inhibitors   Effective diseases 
Antisense oligoDNA  Cancer [48, 174], Nephritis [189],  
  Neointima formation [191] 
siRNA  Cancer [172], Neointima formation [190], 
  Adhesion after surgery [192] 
Aptamer EAE  [87] 
Chondroitin sulfate E  Antibody-induced arthritis [192] 
  For the development and evaluation of other inhibitors, a rapid 
assay system is essential. An assay based on inhibition of the MK-
dependent migration of UMR106 osteoblast-like cells was recently 
developed [193]. In this assay, migrating cells are colorimetrically 
determined. Although many cells, which respond to MK strongly, 
are primary cultured cells, UMR106 cells are an established cell 
line, and time-consuming procedures of cell preparation can be 
avoided. In the assay, MK is provided as a substratum-bound form. 
While soluble MK elicits various cellular responses, its level of 
activity is usually 2-3 times of the preexisting level. Substratum-
bound MK often evokes a stronger response. Thus, the inhibition of 
substratum-bound MK is generally more convenient for testing MK 
inhibitors. Although aptamers to MK were screened by this assay, 
the selected aptamer inhibited activity of soluble MK to suppress 
the expansion of regulatory T cells [87]. Other candidate assays to 
screen MK inhibitors may be the inhibition of MK-dependent sur-
vival of embryonic neurons from MK-deficient mice and inhibition 
of MK-induced cytokine production by human leukocytes. 
  An aptamer to MK has already been used to treat EAE in mice, 
and might become clinically useful [87]. On the other hand, low 
molecular weight compounds with MK inhibitory activity are at the 
initial stages of development. Because of the presence of libraries 
of drug-like compounds such as the Zinc library and efficient in 
silico docking programs, it is not difficult to search for candidate 
MK inhibitors in drug-like compounds. Selected candidate com-
pounds can then be tested for actual MK inhibitory activity. Indeed, 
in such a study [193], two compounds with MK-inhibitory activity 
were found; they did not exhibit adverse cytotoxicity. One com-
pound was 2-(2,6-dimethylpiperidin-1-yl)-4-thiophen-2-yl-6-
(trifluoromethyl)pyrimidine (PubChem 4603792) and the other had 
a similar structure (Fig. 4). Interestingly, both had a trifluoro resi-
due. Although their MK inhibitory activities were not strong, such 
compounds could be used as a mother compound to develop clini-
cally effective MK inhibitors. Conversion of a methyl group to a 
carboxyl group was even proposed as a means to produce a more 
potent inhibitor [193]. 
  In the study mentioned above [193], only a fraction of the Zinc 
library was in silico surveyed, and among numerous compounds 
with potential MK inhibitory activity, only those available from a 
company, Chem. Div., were used to test actual MK inhibitory activ-
ity. Thus a more systematic study might yield much better inhibi-
tors. Furthermore, only compounds with expected strong affinity   418    Current Pharmaceutical Design, 2011, Vol. 17, No. 5  Takashi Muramatsu 
Fig. (4). Structures of two compounds initially selected as low molecular-
weight MK inhibitors [193]. Upper one, PubChem 4603792; lower one, a 
related compound. 
for a heparin-binding site in the C-half were searched in the above 
study. The requirement of a key arginine residue in the heparin-
binding site for MK activity was indeed verified by site-directed 
mutagenesis [29]. However, other parts of the molecule are also 
required for MK activity. As an example, N-half of MK is neces-
sary for MK dimerization [31], which is essential for part of the 
MK activity. Indeed, N-terminal portion of the molecule was used 
as a dominant-negative MK inhibitor, to analyze its role in neuro-
genesis in the zebrafish [194]. In this connection, a segment of MK 
in the N-domain is conserved between human MK, Xenopus MK 
and zebrafish Mdka (Fig. 1), and might play a critical role in some 
MK activities. Furthermore, some monoclonal antibodies reactive 
with the N-domain inhibited MK activity (Sakuma et al., unpub-
lished). Therefore, low molecular weight compounds which bind to 
the N-domain should be also screened. 
  Fragments from MK receptors also have MK inhibitory activ-
ity. Notably, a peptide derived from  1-integrin moderately inhib-
ited MK activity [193]. Furthermore the N-terminal half of the sec-
ond ligand-binding domain of LRP binds to MK strongly [195]. 
Expression of this protein fragment in G401 Wilms’ tumor cells 
suppresses their growth and colony formation in soft agar [195].  
  Although polyclonal antibodies have been reported to inhibit 
the growth of tumor cells such as G401 Wilms’ tumor cells [47] 
and osteosarcoma cells [126], no monoclonal antibody was able to 
do so, to the best of my knowledge. An aptamer with the ability to 
inhibit EAE did not strongly suppress the growth of tumor cells 
either (unpublished results). MK in tumor cells might form a stable 
complex with cell surface receptors or also act intracellularly, and 
only a fraction of antibodies are able to inhibit MK under such con-
ditions. Further efforts to obtain a monoclonal antibody to inhibit 
MK in tumor cells might yield promising results. 
 Both  chondroitin sulfate E and heparin are known to inhibit 
various MK activities. Heparin strongly binds to many kinds of 
proteins, while the reactivity of chondroitin sulfate E is more lim-
ited. Therefore, chondroitin sulfate E might be more suitable as a 
mother material to design a carbohydrate-based MK inhibitor. 
Chondroitin sulfate E itself was shown to inhibit antibody-induced 
arthritis [192]. It is necessary to determine the minimum length of 
chondroitin sulfate E repeating units to attain strong inhibition. In 
the case of heparin, a fragment of apparent molecular weight more 
than 7,000 is necessary to exhibit strong inhibitory activity [63]. A 
similar result is expected for chondroitin sulfate E. However, some 
portion of the carbohydrate might be required only to maintain the 
three dimensional structure of the chain. If so, chemical modifica-
tion may replace some of the oligosaccharide chain. Furthermore, it 
should be examined whether the introduction of another sulfate 
group to a specific position increases the binding to MK without 
affecting the specificity. In this context, sulfation at 3-position of 
glucuronic acid does not appear to increase the binding to MK. This 
is because natural chondroitin sulfate E, which has considerable 
amounts of glucuronic acid 3-sulfate, binds to MK agarose with an 
affinity similar to enzymatically synthesized chondroitin sulfate E, 
which should lack the additional sulfate group [65].  
  Finally, side effects of MK inhibitors might be restricted, be-
cause of limited expression of MK in adult tissue. Still, based on 
current knowledge on MK, we should remember the possibility that 
MK inhibitors may enhance susceptibility to infection and tissue 
degeneration and hinder tissue regeneration. 
5. CONCLUSION 
  Both MK and MK inhibitors are expected to be useful for 
treatment of diseases in the central nervous system. Many works 
remain to be done about development of clinically applicable MK 
inhibitors. 
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ABBREVIATIONS 
ALK  =  Anaplastic lymphoma kinase 
CMV =  Cytomegalovirus 
EAE  =  Experimental autoimmune encephalitis  
HB-GAM =  Heparin-binding  growth-associated  molecule 
LRP  =  Low density lipoprotein receptor-related protein 
MK =  Midkine 
PTN =  Pleiotrophin 
PTPζ  =  Receptor-like protein tyrosine phosphatase ζ
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